Dr. Mathieu is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
234 Goodman St
Mail Location 0796
Cincinnati, OH 45219Phone+1 513-584-1000- Is this information wrong?
Education & Training
- Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 2010 - 2013
- University of Cincinnati Medical Center/College of MedicineResidency, Internal Medicine, 2006 - 2009
- Meharry Medical CollegeClass of 2005
Certifications & Licensure
- MD State Medical License 2010 - 2025
Publications & Presentations
PubMed
- 2 citationsFDA Approval Summary: Atezolizumab as Adjuvant Treatment following Surgical Resection and Platinum-Based Chemotherapy for Stage II to IIIA NSCLC.Luckson N Mathieu, Erin Larkins, Arup K Sinha, Pallavi S Mishra-Kalyani, Samina Jafri, Shyam Kalavar, Kirsten B Goldberg, Richard Pazdur, Julia A Beaver, Harpreet Sing...> ;Clinical Cancer Research. 2023 Aug 15
- 31 citationsFDA Approval Summary: Pembrolizumab, Atezolizumab, and Cemiplimab-rwlc as Single Agents for First-Line Treatment of Advanced/Metastatic PD-L1-High NSCLC.Oladimeji Akinboro, Erin Larkins, Lee H Pai-Scherf, Luckson N Mathieu, Yi Ren, Joyce Cheng, Mallorie H Fiero, Wentao Fu, Youwei Bi, Shyam Kalavar, Samina Jafri, Pallav...> ;Clinical Cancer Research. 2022 Jun 1
- 43 citationsFDA Approval Summary: Capmatinib and Tepotinib for the Treatment of Metastatic NSCLC Harboring MET Exon 14 Skipping Mutations or Alterations, , , , , , , , , , , , , , , , , , , , , , , , , , , , > ;Clinical Cancer Research. 2021 Aug 3
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: